Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease (2017)
Fonte: The New England Journal of Medicine. Unidade: FM
Assuntos: FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO, COLESTEROL, DOENÇAS CARDIOVASCULARES, ESTUDOS RANDOMIZADOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LINCOFF, A. Michael et al. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. The New England Journal of Medicine, v. 376, n. 20, p. 1933-1942, 2017Tradução . . Disponível em: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1609581. Acesso em: 02 out. 2024.APA
Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., et al. (2017). Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. The New England Journal of Medicine, 376( 20), 1933-1942. doi:10.1056/NEJMoa1609581NLM
Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease [Internet]. The New England Journal of Medicine. 2017 ; 376( 20): 1933-1942.[citado 2024 out. 02 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1609581Vancouver
Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease [Internet]. The New England Journal of Medicine. 2017 ; 376( 20): 1933-1942.[citado 2024 out. 02 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1609581
